SCHEMBL2289363

SCHEMBL2289363

CON1C(=O)CCC(=O)[C@]1(C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)O)C(C)C

nearest known ligand 0.42

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ELANE P08246 14/20 0.42
XIAP P98170 2/20 0.40
CMA1 P23946 3/20 0.38
MLX Q9UH92 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8662040 0.97 ELANE (0.40) ELANEXIAPCMA1MLX
SCHEMBL228960 0.90 ELANE (0.38) ELANEXIAPCMA1MLX
SCHEMBL5487413 0.90 ELANE (0.38) ELANEXIAPCMA1MLX
SCHEMBL3276266 0.88 ELANE (0.42) ELANEXIAPCMA1MLX
SCHEMBL535732 0.88 ACE (0.40)
SCHEMBL230923 0.85 ELANE (0.33) ELANECMA1
SCHEMBL5494650 0.85 ELANE (0.40) ELANEXIAPCMA1MLX
SCHEMBL847832 0.84 CMA1 (0.49) XIAPCMA1
SCHEMBL387694 0.83 TACR1 (0.40) ELANEXIAPCMA1MLX
SCHEMBL8661389 0.81 ELANE (0.36) ELANECMA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0964690-B1 PEPTIDE-LIPID CONJUGATES, LIPOSOMES AND LIPOSOMAL DRUG DELIVERY LIPOSOME CO INC (US) 2003-07-09 EP claimed
US-6143716-A CONTROLLED DELIVERY SYSTEM TO DELIVER LIPOSOMAL DRUGS IN VITRO OR IN VIVO, FOR EXAMPLE, IN TREATMENT OF MAMMALS AFFLICTED WITH VARIOUS DISEASES, DISORDERS OR CONDITIONS, E.G., CANCERS THE LIPOSOME COMPANY, INC. (US) 2000-11-07 US claimed
US-6087325-A CONJUGATE OF CERTAIN PEPTIDES TO PHOSPHATIDYLETHANOLAMINES, INCORPORATED INTO LIPOSOMES SO AS TO SELECTIVELY DESTABILIZE THE LIPOSOMES IN THE VICINITY OF TARGET PEPTIDASE-SECRETING CELLS, HENCE DELIVER THE LIPOSOMES THE LIPOSOME COMPANY, INC. (US) 2000-07-11 US claimed
EP-0964690-A4 PEPTIDE-LIPID CONJUGATES, LIPOSOMES AND LIPOSOMAL DRUG DELIVERY LIPOSOME CO INC (US) 2000-03-29 EP claimed
EP-0964690-A1 PEPTIDE-LIPID CONJUGATES, LIPOSOMES AND LIPOSOMAL DRUG DELIVERY THE LIPOSOME COMPANY, INC. (US) 1999-12-22 EP claimed
WO-1998016240-A1 PEPTIDE-LIPID CONJUGATES, LIPOSOMES AND LIPOSOMAL DRUG DELIVERY THE LIPOSOME COMPANY, INC. (US) 1998-04-23 WO claimed
US-20250099625-A1 TANDEM MOLECULAR FLUORESCENCE REPORTERS FOR DETECTION OF TUMOR-INFILTRATING LEUKOCYTES NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2025-03-27 US disclosed
CN-119157801-B Preparation method of nitraria seed extract, and product and application thereof 云南特色植物提取实验室有限公司 2025-03-21 CN disclosed
CN-119157801-A Preparation method of nitraria seed extract, and product and application thereof 云南云科特色植物提取实验室有限公司 2024-12-20 CN disclosed
CN-119074712-A Application of elastase inhibitor in preparation of medicine for treating cerebral hypoperfusion 首都医科大学附属北京天坛医院 2024-12-06 CN disclosed
CN-119015448-A Methods and compositions related to therapeutic peptides for cancer therapy 芝加哥大学 2024-11-26 CN disclosed
CN-119031931-A Protease 3 (PR 3) chimeric autoantibody receptor T cells and related methods and uses 朱诺治疗学股份有限公司 2024-11-26 CN disclosed
CN-118286123-B Rosa roxburghii fruit extract prepared by microbial fermentation and preparation method and application thereof 广州君奕科技有限公司 2024-11-15 CN disclosed
US-6087325-A CONJUGATE OF CERTAIN PEPTIDES TO PHOSPHATIDYLETHANOLAMINES, INCORPORATED INTO LIPOSOMES SO AS TO SELECTIVELY DESTABILIZE THE LIPOSOMES IN THE VICINITY OF TARGET PEPTIDASE-SECRETING CELLS, HENCE DELIVER THE LIPOSOMES THE LIPOSOME COMPANY, INC. (US) 2000-07-11 US disclosed
EP-0964690-A4 PEPTIDE-LIPID CONJUGATES, LIPOSOMES AND LIPOSOMAL DRUG DELIVERY LIPOSOME CO INC (US) 2000-03-29 EP disclosed
EP-0964690-A1 PEPTIDE-LIPID CONJUGATES, LIPOSOMES AND LIPOSOMAL DRUG DELIVERY THE LIPOSOME COMPANY, INC. (US) 1999-12-22 EP disclosed
WO-1998016240-A1 PEPTIDE-LIPID CONJUGATES, LIPOSOMES AND LIPOSOMAL DRUG DELIVERY THE LIPOSOME COMPANY, INC. (US) 1998-04-23 WO disclosed
EP-0475160-B1 Preparation for drug application in minute droplet form IDEA AG (DE) 1996-02-14 EP disclosed
EP-0475160-A1 Preparation for drug application in minute droplet form Cevc, Gregor, Prof. Dr. (DE) 1992-03-18 EP disclosed
WO-1992003122-A1 PREPARATION FOR APPLICATION OF ACTIVE SUBSTANCES IN THE FORM OF MINIMUM-SIZED DROPLETS CEVC GREGOR (DE) 1992-03-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250099625-A1 TANDEM MOLECULAR FLUORESCENCE REPORTERS FOR DETECTION OF TUMOR-INFILTRATING LEUKOCYTES GZMB, GUSB, MKI67 ELANE 181/4885XIAP 1492/4885CMA1 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.